Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02319304 · ClinicalTrials.gov registry record · Phase 2
Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02319304 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 3 participants.
The verdict
NCT02319304, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects, both good and bad, of adding very low dose fractionated radiation therapy (LDFRT) to the pelvis, with FOLFOX chemotherapy prior to surgery. Standard pelvic radiation therapy given once a day (Monday through Friday) over approximately 5.5 weeks is not given in this study. You will receive 6 cycles of FOLFOX (each cycle is 2 weeks) and you will also get an LDFRT to your pelvis given twice a day on the first two days of each cycle.
Interventions
- DRUG FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}
- RADIATION Low dose fractionated radiation therapy (LDFRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02319304
The ClinicalTrials.gov registry entry for NCT02319304 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin} is the first listed.
NCT02319304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02319304 about?
NCT02319304 is a clinical study titled "Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma". The purpose of this study is to assess the effects, both good and bad, of adding very low dose fractionated radiation therapy (LDFRT) to the pelvis, with FOLFOX chemotherapy prior to surgery. Standard pelvic radiation therapy given once a day (Monday through Friday) over approximately 5.5 weeks is n...
What is the current status of trial NCT02319304?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2015-03. Estimated completion is 2018-10-05.
What interventions are being tested in trial NCT02319304?
The interventions under investigation include: FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin} (DRUG), Low dose fractionated radiation therapy (LDFRT) (RADIATION).
Who is sponsoring clinical trial NCT02319304?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.